4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-25-243819
Chief Executive Officer sold 50,895 shares at $67.91 ($3,456,279)
- Chief Executive Officer acquired 100,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kulkarni Samarth · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-10-16 | Exercise or conversion : show line 1 in the form | +100,000 | 305,096 | D | ||
| 2025-10-17 | Sale : show line 2 in the form | −50,895 | $67.91 | $3,456,279 | 254,201 | D |
| Open-market sales · 50,895 sh · avg $67.91 · $3,456,279 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-10-16 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −100,000 | 300,000 | D |
Loading xslF345X05/ownership.xml…